Table 2.
Novel therapeutics for pemphigus.
| Therapeutics | Target | Development |
|---|---|---|
| Rituximab | CD20 | First-line treatment combined with short-term systemic corticosteroids |
| Veltuzumab | CD20 | Approved by FDA for the treatment of patients with pemphigus with orphan drug status |
| Ofatumumab | CD20 | A double-blind, randomized, placebo-controlled, phase 3 clinical trial was completed (NCT01920477) |
| PRN1008 | BTK | A randomized, double-blind, placebo-controlled, phase 3 clinical trial is ongoing (NCT03762265) |
| CAAR-T cells | Anti-Dsg3 B cells | Preclinical models |
| VAY736 | BAFF-R | A randomized, placebo-controlled, double-blind, phase 2 clinical trial is ongoing (NCT01930175) |
| SYNT001 | Neonatal Fc receptor | A clinical trial is currently ongoing (NCT03075904) |
| Argx-113 | Neonatal Fc receptor | A clinical trial is currently ongoing (NCT03334058) |
| PolyTregs | A nonrandomized, open-label, phase 1 clinical trial is ongoing (NCT03239470) |